Lyell Immunopharma Stock Fair Value Calculation – LYELL IMMUNOPHARMA Reports Q2 FY2023 Earnings Results

August 10, 2023

🌥️Earnings Overview

For the second quarter of FY2023 ending June 30, 2023, LYELL IMMUNOPHARMA ($NASDAQ:LYEL) reported total revenue of USD 0.0 million, representing a year-over-year decrease of 99.9%. The company posted a net income of USD -63.9 million, a lower figure compared to the -36.3 million reported for the same period in the previous year.

Price History

On Tuesday, LYELL IMMUNOPHARMA reported their quarterly earnings results for the second quarter of FY2023. The stock opened at $2.3 and closed at $2.4, up 1.9% from the previous closing price of $2.4. This increase in stock price is indicative of the company’s positive performance for the quarter. LYELL IMMUNOPHARMA’s growth is largely attributed to their research and development efforts in immunotherapy drugs for cancer treatment. The company’s innovative drug candidates are being developed to target specific cancers, providing patients with improved treatment options with fewer side effects.

The company has also expanded its global presence, having recently entered into strategic partnerships with key pharmaceutical companies around the world. This will enable LYELL IMMUNOPHARMA to bring their innovative immunotherapies to a wider patient population, thereby further driving their growth and results. Based on the Q2 FY2023 results, investors remain optimistic about LYELL IMMUNOPHARMA’s future prospects. The company is expected to continue to expand their product pipeline and enter into new strategic partnerships, which will help them to further drive their growth and financial performance in the quarters ahead. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Lyell Immunopharma. More…

    Total Revenues Net Income Net Margin
    48.48 -209.5 -395.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Lyell Immunopharma. More…

    Operations Investing Financing
    -162.74 174.63 6.75
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Lyell Immunopharma. More…

    Total Assets Total Liabilities Book Value Per Share
    835.35 98.5 2.95
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Lyell Immunopharma are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    405.1% -432.5%
    FCF Margin ROE ROA
    -356.0% -17.2% -15.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Lyell Immunopharma Stock Fair Value Calculation

    At GoodWhale, we conducted an analysis of LYELL IMMUNOPHARMA‘s wellbeing. Our proprietary Valuation Line suggests that the fair value of LYELL IMMUNOPHARMA share is around $22.0. However, currently the stock is traded at $2.4 – undervalued by 89.1%, presenting a great opportunity for investors. Therefore, we would recommend investors to consider investing in LYELL IMMUNOPHARMA stock at this time. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The biopharmaceutical industry is experiencing an intense competition between Lyell Immunopharma Inc and its competitors, Humanigen Inc, Surrozen Inc, and US Stem Cell Inc. These companies are striving to develop groundbreaking treatments for various diseases and conditions, making them fierce rivals in the market. Each company is vying for a top spot in the industry with their innovative research and products, hoping to gain recognition and success.

    – Humanigen Inc ($NASDAQ:HGEN)

    Humanigen Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious illnesses. Its market cap of 14.29 million as of 2022 indicates that it is a relatively small company in the biopharmaceutical industry. Its return on equity of 128.19% is significantly higher than the industry average, which indicates that the company is making effective use of its resources to generate profits. Humanigen has developed a number of treatments that have shown early promise in clinical trials, and it is likely that the company will continue to grow and develop new treatments in the future.

    – Surrozen Inc ($NASDAQ:SRZN)

    Surrozen Inc is a biotechnology company focused on developing treatments and therapies for autoimmune diseases and regenerative medicine. The company has a market cap of 17.31M as of 2022, indicating that it is a relatively small-cap company. Its Return on Equity of -46.6% indicates that the company has not been profitable in recent years, likely due to its high R&D costs associated with developing new treatments.

    – US Stem Cell Inc ($OTCPK:USRM)

    US Stem Cell Inc is a leading biotechnology company that focuses on developing and commercializing novel stem cell treatments for a range of medical conditions. With a market cap of 3.05M as of 2022 and a Return on Equity of 8.54%, US Stem Cell Inc is well positioned to continue its successful track record of innovative stem cell treatments and therapies. The company’s market cap reflects the current value of its equity, while the Return on Equity (ROE) measures the efficiency of US Stem Cell Inc’s management in generating profits from its shareholders’ equity. The higher the ROE, the more efficient management is in generating profits. As such, US Stem Cell Inc’s 8.54% ROE indicates that it is doing well in generating returns for its shareholders.


    Investors should be cautious of investing in LYELL IMMUNOPHARMA. The company reported a total revenue of USD 0.0 million for the second quarter of FY2023, a year-over-year decrease of 99.9%. Its reported net income was USD -63.9 million, down from the figure of -36.3 million from the same period in the previous year.

    This suggests an overall decrease in the company’s financial performance, indicating that it is not well positioned to generate profits for shareholders. Therefore, investors should thoroughly research and assess the company’s financials and prospects before making any investment decision.

    Recent Posts

    Leave a Comment